IMUX

Immunic, Inc. is a clinical-stage biopharmaceutical company developing selective oral therapies for chronic inflammatory and autoimmune diseases. The company's lead programs focus on treatments for ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis, as well as relapsing-remitting multiple sclerosis. Immunic's pipeline is built around novel immunology-based mechanisms, including DHODH inhibition and inverse agonism of RORγt. The company aims to provide patients with oral treatment options that offer improved efficacy and safety profiles compared to existing therapies.